Tarsier Pharma, Roche, Eli Lilly and Company, Oculis, Acelyrin/ Affibody ... - The Globe and Mail

Retrieved on: 2024-05-03 14:42:59

Tags for this article:

Click the tags to see associated articles and topics

Tarsier Pharma, Roche, Eli Lilly and Company, Oculis, Acelyrin/ Affibody ... - The Globe and Mail. View article details on hiswai:

Summary

The article discusses the growth of the uveitis market, valued at approximately USD 1,544 million in 2023, with forecasts up to 2034. The study focuses on the epidemiology, market trends, and key therapies like Adalimumab and their impact on conditions like uveitic glaucoma, with insights from the National Eye Institute.

Article found on: www.theglobeandmail.com

View Original Article